Overview

Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy works in treating patients with acute promyelocytic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Cancer Institute (NCI)
Treatments:
6-Mercaptopurine
Arsenic Trioxide
Cytarabine
Daunorubicin
Mercaptopurine
Methotrexate
Tretinoin